Silo Pharma, Inc. — Form 8-K
Filed November 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 71/100
What the filing says
Silo Pharma (market cap ~$5.3M) executed a private placement on November 5, 2026, selling up to $1.1 million aggregate of common shares and pre-funded warrants to accredited investors at $1.50 per share (warrant exercise price $0.0001). The offering includes registration rights and a waiver from H.C. Wainwright. Proceeds are for working capital; use restricted from debt repayment, redemptions, litigation settlement, and FCPA/OFAC violations.
Why this rating
Capital raise of $1.1M represents ~21% of $5.3M market cap—material for survival and operations. Immediate cash infusion aids liquidity. Pre-funded warrants create dilution and downward price pressure risk. Positive: working capital; Negative: significant shareholder dilution, hedging risk acknowledged in covenant.
Tradability signal
NO TRADE
No trade: only ~$0k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.41 ▲ 6.01% | at our read · unknown $1.33 | +10 min · unknown $1.46 ▲ 9.77% | +30 min · unknown $1.48 ▲ 10.90% | +1 hr · unknown $1.52 ▲ 14.66% | +4 hrs · unknown $1.64 ▲ 23.08% |
The stock had already moved -5.67% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.